– FPI-1434 Phase 1 study is progressing – Recent transactions and partnerships expand and diversify Fusion’s pipeline of targeted alpha therapies in development to treat a broad array of tumor types HAMILTON, ON and BOSTON, March 25, 2021 /PRNewswire/ — Fusion Pharmaceuticals Inc….